0001193125-26-216752
SEC filingAN2 Therapeutics reported Q1 2026 net loss of $10.0 million with R&D expenses down to $6.7 million, cash position of $85.3 million extended into 2029 after $40 million private placement, and pipeline advances including Phase 2 initiations.
AN2 Therapeutics reported a Q1 2026 net loss of $10.0 million, an improvement from $10.6 million in Q1 2025, primarily due to reduced R&D expenses of $6.7 million versus $7.7 million prior year. The decline in R&D reflected lower chemistry manufacturing and controls costs after completing certain program activities, and reduced license fees, though partially offset by rises in personnel, clinical trials, consulting, and facilities expenses. G&A expenses remained stable at $3.8 million. Interest income fell to $0.5 million from $0.9 million due to lower cash balances and interest rates. CEO Eric Easom highlighted pipeline momentum, including advancing oral epetraborole toward a Phase 2 trial in phlebotomy-dependent polycythemia vera (PV) in Q3 2026, supported by preclinical and clinical-enabling data for this blood cancer affecting ~155,000 U.S. patients. Patient screening began in March 2026 for a Phase 2 investigator-initiated trial of epetraborole in M. abscessus lung disease, with topline data expected late 2027. For Chagas disease, dosing completed in Phase 1 of AN2-502998, with human and non-human primate data due in Q2 2026 to inform a planned Phase 2 later in 2026. The company declared an ENPP1 candidate for solid tumors, leveraging its boron chemistry platform's advantages in targeting difficult oncology and bone disorder proteins. Balance sheet strengthened to $85.3 million in cash, equivalents, and investments at quarter-end, bolstered by $40 million gross proceeds from a March 2026 private placement, projecting runway into 2029. Three Phase 2 programs are expected to advance this year, positioning AN2 to deliver readouts across hematologic, infectious, and oncology indications.